Date: 29th January 2020 **Sydney, Australia**

Noxopharm Non-Deal Roadshow Presentation

Sydney, 29th January 2020: Noxopharm (ASX: NOX) is pleased to provide shareholders and the market the attached Noxopharm corporate presentation "Non-Deal Roadshow Presentation".

This document is being used by Noxopharm for presentation during a non-deal roadshow by the company in Melbourne and Sydney on the 29th and 30th January 2020.

The presentation can be found at www.noxopharm.com

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc.

www.noxopharm.com

Investor & Corporate Enquiries:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media queries:
Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Graham Kelly, CEO and Chairman of Noxopharm has approved the release of this document to the market.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks,

uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Noxopharm Limited

Veyonda®

Non-Deal Roadshow Presentation

NOXOPHARM

ASX: NOX

DISCOVER DEVELOP DELIVER

Disclaimer

This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

NOXOPHARM

Non-Deal Roadshow Presentation

1	Dr Gisela Mautner Medical Overview
2	Mr Alex Hunter Corporate Overview

NOXOPHARM

Veyonda®

Noxopharm is seeking to bring Veyonda® to market as a first-in-class drug that combines with radiotherapy to provide a potent anti-cancer effect in prostate cancer

NOXOPHARM

Dr Gisela Mautner *MD-PHD, MPH, MBA*
Medical Overview

- Drug development process
- Prostate cancer
- Veyonda®
- DARRT
- LuPIN
- Veyonda® market potential
- Indicative clinical program timing

NOXOPHARM

Veyonda®

Drug Development Process



NOXOPHARM



1 in 5 men

develop prostate cancer before they turn 85

NOXOPHARM

Prostate Cancer and Treatment Options



NOXOPHARM

Veyonda® Acts in a Unique Space



Irrespective of how many new drugs are coming to market, they will generally not affect Veyonda's space

NOXOPHARM

Veyonda® – Clinical Study DARRT-1

- 26 men enrolled with late-stage **prostate cancer**
- Metastatic castration-resistant prostate cancer (mCRPC)
- Progressive disease
- No remaining standard treatment options
- Eligible for palliative RT for symptomatic relief

- Treatment with low-dose RT (20Gy in 5 fractions) and 14 days of NOX66 (400, 800, 1200 mg)



Bone scan with metastatic disease

DARRT = Direct and Abscopal Response to Radiation Therapy; RT = Radiation Therapy

NOXOPHARM

DARRT-1: Safety and Tolerability

- Primary end-point of acceptable safety and tolerability was met
- Treatment well tolerated with no serious side-effects due to Veyonda®
- No dose-limiting toxicities

✓ Veyonda® in combination with radiation therapy was reported to be **safe and well-tolerated**[1]

1. Noxopharm. Data on file.

NOXOPHARM

DARRT-1: Efficacy – Tumour Response

- In the 15* patients who were evaluable at 6 months[1]

The Tumours stopped growing or reduced in size in 10 patients

(1 patient achieved a partial response and 9 achieved stable disease at 6 months)

6-months follow up	First part 400mg, 800mg & 1200mg (Reported on 12 November 2019)	Expansion part 1200mg	Overall All doses (Reported on 2 December 2019)
Overall (RECIST1.1)	N=10	N=5	N=15
Complete response	0	0	0
Partial response	1 (10%)	0	1 (7%)
Stable disease	7 (70%)	2 (40%)	9 (60%)
Progressive disease	2 (20%)	3 (60%)	5 (33%)

** 10 patients lost to follow-up, were not measurable, withdrew from study or died (unrelated to treatment)*

1. Noxopharm. Data on file.

NOXOPHARM

DARRT-2 – In Planning

- Building on the experience and data of DAART-1
- Phase 2 trial
- Multinational
- Min. 60 patients
- Same patient population as in DARRT-1
- Radiation therapy plus repeated cycles of Veyonda®
- Medical Advisory Boards established
- Protocol synopsis being drafted
- Anticipated regulatory submissions late-2020
- Study expected to commence in early-2021

✓ **We are developing the most efficient and impactful study possible!**

NOXOPHARM

Additional Opportunity in Prostate Cancer

External Radiation

- Standard-of-Care
- Widely used

DARRT

Internal Radiation

- Experimental
- Billion-dollar Acquisition by Novartis



LuPIN

NOXOPHARM

LuPIN – Comparative Results

- Progression-free survival (PFS) is a measure of the time from the start of treatment until the disease progresses.

✓ Median PFS **quadrupled** through the addition of Veyonda® (8.4 months vs 2.0 months with ^{177}Lu-PSMA alone)

- Treatment duration

✓ The addition of Veyonda® meant that the number of men able to start the 4th treatment cycle **tripled** to 69% from 21% with ^{177}Lu-PSMA alone

✓ The combination therapy also was well tolerated, pointing to Veyonda® being safe to use in combination with intravenous radiotherapy

In summary, combination therapy of Veyonda® and ^{177}Lu-PSMA-617 shows benefits to patients well above that achieved with ^{177}Lu-PSMA-617 therapy alone and underscores the Company's confidence in Veyonda® eventually becoming a standard drug in the management of prostate cancer

NOXOPHARM

Market Potential – Prostate Cancer



NOXOPHARM

Market Opportunities – RT plus Veyonda®



NOXOPHARM

Indicative Clinical Program Timing

DARRT -1 complete, final statistical results due March 2020

DARRT-2 protocol development under way

DARRT-2 clinical trial indicative commencement early 2021

Indicative Clinical Program Timing	
DARRT-1	
Phase 1 clinical trial complete	Dec Q 2019
Phase 1 statistical report	Mar Q 2020
DARRT-2	
Protocol Development/CRO appoin't	now- Sep Q 2020
•Medical advisory board consultation	
•Appoint CRO	
Commence trial (indicative)	Early 2021
DARRT-2 trial under way (indicative)	2021 onwards
LuPIN	
Trials complete	Dec Q 2020
Commercial partnerships	2020 & 2021



NOXOPHARM

Mr Alex Hunter *MBA, BE, GradDipCorpSecFinLaw, GradDipAppFin*

Corporate Overview

- Executive Summary
- Company Details
- Market Opportunity
- Nyrada Inc.
- Investment Highlights

NOXOPHARM

Veyonda®

Executive Summary

- Australian biotech company listed on Australian Securities Exchange (ASX:NOX)
- Oncology focus
- Proprietary drug Veyonda® well advanced in clinical development phase
- First-in-class inhibitor of sphingosine-1-phosphate
- Intended as adjunct to radiotherapy
- 2 active clinical trials studying improved efficacy of radiotherapy in late-stage **mCRPC**:
  - (Phase 1b) DARRT, Veyonda® + external beam radiotherapy
  - (Phase 2a) LuPIN, Veyonda® + ^{177}Lu-PSMA-617
  - Strong clinical signals achieved in both trials
- Preparing for Phase 2 DARRT clinical trial
- Unique dual market opportunity for Veyonda® in late-stage prostate cancer space
- ~30% equity in Nyrada Inc., a promising listed subsidiary focused on novel small molecule drugs (ASX:NYR)
- Experienced board and management team, strong technical & commercial experience

Noxopharm believes that its DARRT and LuPIN treatments will become standard of care for late-stage prostate cancer, offering patients and doctors two new treatment options

NOXOPHARM

Company Details

Noxopharm Limited *(Jan 2020)*	
Listed on Australian Securities Exchange (ASX:NOX) Aug 2016	
Shares on issue	132m
Share Price	A$0.23.5-A$0.29
Market Cap	A$31-38m
Cash	A$1.7m
Convertible notes	A$4.7m

Board and Key Management	
Dr Graham Kelly. *PhD*	Chairman & CEO
Ian Dixon. *PhD, MBA*	Non-Executive Director
Peter Marks. *MBA, BEc, LLB*	Non-Executive Director
Dr Gisela Mautner. *MD-PHD, MPH, MBA*	Chief Medical Officer
Alex Hunter. *MBA, BE*	Chief Commercial Officer
Greg Ambra. *MS*	SVP North American Ops
Dr John Wilkinson. *PhD*	Chief Scientific Officer
Shawn Van Boheemen. *BBus MCom*	Chief Financial Officer



NOXOPHARM

Market Opportunity

Noxopharm believes Veyonda® has potential use in most forms of solid cancer

*Noxopharm believes the fastest, lowest risk path to market for Veyonda® is as a treatment for **mCRPC***

***mCRPC** currently is treated palliatively. Noxopharm is intended to go beyond palliation and provide a meaningful, durable and well tolerated anti-cancer effect*

Market Opportunity

- Noxopharm believes Veyonda® has potential applications in most forms of solid cancer as both a radio-enhancer and chemo-enhancer
- Noxopharm has selected radio-enhancement (**DARRT regimen**) in **metastatic prostate cancer (mCRPC)** as the path to first market approval:
  - DARRT-1 has shown that Veyonda® provides a meaningful anti-cancer effect including cessation of tumour growth in about half of mCRPC patients, and considerable (average 80%) pain relief
  - Management of mCRPC is a major unmet need, with palliative treatment the current standard of care
  - The need is predicted to grow with increasing longevity and a growing global middle class
  - Ease of enrolment due to high disease incidence and 12-months end-points (limited life expectancy of typically 6-9 months) suggests relatively short trial duration
  - Potential high demand and low drug costs could result in blockbuster revenue
- A number of recent multi-billion dollar deals in the mCRPC space (see table below)

Recent acquisitions	Buyer	Seller	Price range
XTANDI® mCRPC (2016)	Pfizer	MEDIVATION	US$14 billion
^{177}Lu-PSMA-617 mCRPC (2018)	NOVARTIS	ENDOCYTE	US$2.1 billion
^{177}Lu-PSMA-617 & others mCRPC (2018)	NOVARTIS	Advanced Accelerator Applications	US$3.9 billion

2019 Prostate Cancer	Australia	USA
New cases of Prostate Cancer diagnosed	19,500	175,000
Deaths from Prostate Cancer	3,300	31,600

NOXOPHARM

Nyrada Inc. (ASX:NYR)

*Noxopharm's shareholding in Nyrada has a market value of **$10-14m** based on Nyrada's recent trading range*

NYRADA

- Nyrada is a pre-clinical stage, drug company specialising in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases
- Nyrada listed on the ASX on 16th January 2020
- The Company's vision is to become a high growth pharmaceutical company specialising in drug discovery where few if any, effective or well-tolerated therapies exist
- The Company has four current drug development programs:
    - Cardiovascular: A PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to, or unable to take statin drugs
    - Neuroprotection: A neuroprotectant drug to improve patient outcomes and prevent long-term disability in patients with ischaemic stroke and traumatic brain injury
    - Inflammation/pain: A drug to treat pain associated with peripheral nerve damage (such as sciatica), and
    - Inflammation/autoimmunity: A drug to treat autoimmune diseases such as psoriasis

Nyrada Share price trading range	Noxohparm shareholding*	Implied market value NOX shareholding
$0.215	45,373,845	$9.8m
$0.305		$13.8m

* Includes 33.4m CDI's and 12m performance shares

Board and Key Management	
John Moore	Non-executive Chairman
Dr Graham Kelly PhD	Founder, Non-exec Director
Peter Marks	Non-executive Director
Marcus Frampton	Non-executive Director
Rudiger Weseloh PhD	Non-executive Director
Christopher Cox	Non-executive Director
James Bonnar	Chief Executive Officer
Benny Evison PhD	Chief Scientific Officer

NOXOPHARM

Investment Highlights

Noxopharm Investment Highlights

- **Significant clinical milestones** over next 12 months from DARRT and LuPIN trials
- **Potential standard of care**: Noxopharm believes that its DARRT and LuPIN treatments have the potential to become standard of care for late-stage prostate cancer where treatment currently is palliative
- **Potential dominant position:** Company in unique position of having two potential treatments for late-stage mCRPC, providing a likely dominant position in a critical sector
- **DARRT marketing approval**: With planning now in progress for DARRT-2 pivotal trial, Company within reach of Veyonda® generating significant revenue
- **LuPIN treatment**: Current LuPIN clinical trial suggesting that Veyonda® is at least doubling the anti-cancer activity of ^{177}Lu-PSMA-617, a drug candidate the subject of a US$6 billion series of acquisitions in 2018
- **Broader market opportunity**: Approval of Veyonda® for mCRPC cancers (DARRT & LuPIN), including early-stage prostate cancer, likely to substantially increase the commercial value of the Company
- **Equity in Nyrada** provides additional corporate value $10-15m

Contact Details

Australia

Dr Graham Kelly – Chairman & CEO
+61 429 854 390
graham.kelly@noxopharm.com

Dr Gisela Mautner – Chief Medical Officer
+61 499 005 012
gisela.mautner@noxopharm.com

Australia

Alex Hunter –Chief Commercial Officer
+61 467 570 063
alex.hunter@noxopharm.com

USA

Greg Ambra – Senior VP North America Operations
+1 732 595 7508
greg.ambra@noxopharm.com

NOXOPHARM

For further information please visit

www.noxopharm.com

Veyonda®

NOXOPHARM

ASX: NOX

DISCOVER DEVELOP DELIVER